Company Overview

AVITA Medical, Inc. is a commercial-stage regenerative medicine company focused on the treatment of acute and chronic wounds. The company operates within the medical devices and regenerative medicine industries, with its core technology centered on the rapid regeneration of a patient’s own skin. AVITA Medical’s primary product is the RECELL® System, an autologous cell harvesting device that enables clinicians to create a regenerative skin cell suspension at the point of care, significantly reducing the need for traditional skin grafting.

The company primarily serves burn centers, trauma hospitals, and specialized surgical facilities, with its strongest market presence in severe burn treatment. AVITA Medical is strategically positioned through its differentiated technology, which offers clinical and economic advantages by reducing donor site morbidity, hospital length of stay, and overall treatment costs. Originally founded in Australia, the company transitioned its strategic focus to the United States following regulatory milestones and commercial adoption, culminating in its redomiciliation to the U.S. and listing on Nasdaq under the ticker RCEL.

Business Operations

AVITA Medical generates revenue primarily through the sale and utilization of the RECELL® System, including disposable kits and associated consumables. The company operates as a single-reportable segment focused on regenerative medicine solutions for skin restoration. Revenue is largely procedure-based, driven by the volume of RECELL treatments performed in approved indications, particularly thermal burns.

Operationally, AVITA Medical maintains commercial, regulatory, and clinical operations in the United States, supported by international activities in Australia, Europe, and select global markets. The company controls proprietary cell-processing technology and manufacturing processes while relying on a combination of internal teams and third-party partners for distribution, logistics, and certain manufacturing components. Its U.S. commercialization strategy is supported by direct sales teams targeting verified burn centers.

Strategic Position & Investments

AVITA Medical’s strategic direction is focused on expanding the clinical indications and addressable market for the RECELL® System. Growth initiatives include pursuing additional regulatory approvals, increasing penetration within existing U.S. burn centers, and expanding into soft tissue reconstruction and trauma-related skin defects. The company continues to invest in clinical trials to support label expansions and reimbursement coverage.

Rather than pursuing large-scale acquisitions, AVITA Medical has prioritized internal investment in clinical evidence generation, physician education, and health economics outcomes research. The company has also explored next-generation regenerative technologies adjacent to its core platform, although publicly available sources indicate that its primary strategic investment remains centered on expanding RECELL’s use across new indications and patient populations. Data inconclusive based on available public sources regarding material joint ventures or significant minority investments.

Geographic Footprint

AVITA Medical is headquartered in Valencia, California, and maintains a strong operational and commercial presence across the United States, which represents its largest revenue-generating region. The U.S. market is the company’s primary strategic focus due to favorable reimbursement dynamics and regulatory approvals.

Internationally, the company has historical roots and ongoing operations in Australia, along with regulatory approvals and limited commercial activity in Europe, Japan, and parts of Asia-Pacific. While international revenue remains a smaller portion of total sales, these regions represent long-term growth opportunities as regulatory pathways and clinical adoption progress.

Leadership & Governance

AVITA Medical is led by an executive team with experience in medical devices, biotechnology, and commercial-stage healthcare companies. The leadership emphasizes disciplined commercialization, clinical evidence generation, and long-term value creation through innovation in regenerative medicine.

Key executives include:

• Jim Corbett – President and Chief Executive Officer
• Michael Perry – Chief Financial Officer
• Andrew Quick – Chief Operating Officer
• Dale Sander – Chief Commercial Officer
• Alison R. Sutherland – Chief Legal Officer and Corporate Secretary

The company operates under a governance framework aligned with U.S. public company standards, with oversight from an independent board of directors and a strategic vision centered on improving patient outcomes while driving sustainable revenue growth.